c-Met/HDAC-IN-3

Cat. No.:	HY-150004
CAS No.:	2439175-23-0
Molecular Formula:	$C_{34}H_{35}FN_4O_7$
Molecular Weight:	630.66
Target:	c-Met/HGFR; HDAC; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

c-Met/HDAC-IN-3 (Compound 15f) is a dual c-Met and HDAC inhibitor with IC_{50} values of 12.50 nM and 26.97 nM against c-Met and HDAC1, respectively. c-Met/HDAC-IN-3 induces apoptosis and cause cell cycle arrest in G2/M phase[1].

IC_{50} & Target

c-Met	HDAC1
12.50 nM (IC_{50})	26.97 nM (IC_{50})

In Vitro

c-Met/HDAC-IN-3 (Compound 15f) (0-20 μM, 72 h) shows antiproliferative activities against HCT-116, MCF-7 and A549 cells[1].
c-Met/HDAC-IN-3 (0-5 μM, 48 h) induces apoptosis and arrests cell cycle at G2/M phase[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line:	HCT-116, MCF-7 and A549
Concentration:	0-20 μM
Incubation Time:	72 h
Result:	Showed antiproliferative activities with IC_{50} values of 0.54 ± 0.05, 0.28 ± 0.02 and 1.08 ± 0.44 μM against HCT-116, MCF-7 and A549 cells.

Apoptosis Analysis[1]

Cell Line:	HCT-116
Concentration:	0.2, 1.0 and 5.0 μM
Incubation Time:	48 h
Result:	Resulted in 6.97%, 7.08% and 13.21% cells apoptosis at 0.2, 1.0 and 5.0 μM, respectively.

Cell Cycle Analysis[1]

Cell Line:	HCT-116
Concentration:	0.2, 1.0 and 5.0 μM

Incubation Time:	48 h
Result:	Showed an obvious increase in the proportion of cells in G2/M phase in a dose-dependent manner.

REFERENCES

[1]. Hu H, et al. Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorg Chem. 2020 Aug;101:103970.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA